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Abstract
Background: Local pelvic recurrence after radical cystectomy for muscle invasive bilharzial related squamous cell
carcinoma accounts for 75% of treatment failures even in organ confined tumors. Despite the proven value of
lymphadenectomy, up to 60% of patients undergoing cystectomy do not have it. These factors are in favor of
adjuvant radiotherapy reevaluation. objectives: to evaluate the effect of adjuvant radiotherapy on disease free
survival in muscle invasive bilharzial related squamous cell carcinoma of the urinary bladder and to test the
predictability of radio-sensitivity using the anti apoptotic protein Bcl-XL.
Methods: The study prospectively included 71 patients, (47 males, 24 females) with muscle invasive bilharzial
related squamous cell carcinoma of the bladder (Stage pT2a-T3N0-N3M0) who underwent radical cystectomy in
Assiut university hospitals between January 2005 and December 2006. Thirty eight patients received adjuvant
radiotherapy to the pelvis in the dose of 50Gy/25 fractions/5 weeks (Group 1), while 33 patients did not receive
adjuvant radiotherapy (group 2). Immunohistochemical characterization for bcl-xL expression was done. Follow up
was done every 3 months for 12 to 36 months with a mean of 16 ± 10 months. All data were analyzed using SPSS
version 16. Three years cumulative disease free survival was calculated and adjusted to Bcl-XL expression and side
effects of the treatment were recorded.
Results: The disease free cumulative survival was 48% for group 1 and 29% for group 2 (log rank p value 0.03).
The multivariate predictors of tumor recurrence were the positive Bcl-XL expression (odd ratio 41.1, 95% CI 8.4 -
102.3, p < 0.0001) and radiotherapy (odd ratio 0.19, 95% CI 0.05 - 0.78, p < 0.02). With Cox regression, the only
independent multivariate predictor of radio-sensitivity was the Bcl-XL expression with odd ratio 4.6 and a p value
< 0.0001. All patients tolerated the treatment with no life threatening or late complications during the period of
follow up.
Conclusions: Adjuvant radiotherapy for muscle invasive bilharzial related squamous cell carcinoma of the urinary
bladder has potential effectiveness and minor side effects. Moreover, Bcl-XL expression is a valuable tool for
predicting those who might not respond to this adjuvant treatment.
Background
Bilharzial related squamous cell carcinoma (SCC) occurs
commonly in the Middle East, South-east Asia and
South America where schistosomiasis is endemic [1]. In
Egypt, SCC represents nearly 60 - 67.6% of all bladder
c a n c e r sa n di tu s u a l l yp r e s e n t sa sam u s c l ei n v a s i v e
tumor [2,3]. Local pelvic recurrence after radical cystect-
omy accounts for about 75% of treatment failures even
in those with organ confined tumors. This high inci-
dence of local recurrence highlights the necessity of
using adjuvant therapy (AR) to improve the final treat-
ment outcome [4]. The use of AR after cystectomy has
long lost favor within the oncology community includ-
ing the radiation oncologists. Yet, many oncologists still
believe in the idea of “sterilizing” the pelvis by AR [5].
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predominantly mediated through induction of apoptosis
in tumor cells, de novo or as a result of induced damage
of cellular metabolic processes or cell cycle control
mechanisms. Accordingly, it is possible that tumors
which exhibit apoptosis may be more sensitive to radio-
therapy [6]. Bcl-2 family protein expression modulates
response to radiotherapy where pro-apoptotic members
enhance radio-sensitivity while anti-apoptotic members
like Bcl-XL enhance radio-resistance [7]. Treatment-
refractory cancers from a variety of sites display high
expression of the pro-survival (anti-apoptotic) Bcl-XL
factor [8] which suggests that Bcl-XL participates in
multimodality resistance to radiation [9,10]. Bcl-XL is a
negative prognostic factor in muscle invasive bilharzial
related SCC (MIBR-SCC) of the bladder [11].
To our knowledge no data could be found in the
available literature regarding the importance of Bcl-XL
expression as a predictor of the response to AR among
bilharzial or non- bilharzial bladder cancer patients. It
would be advantageous to know forehand whether a
particular patient will get any benefit in face of the
potential harm due to radiotherapy.
The aim of this prospective study is to test the poten-
tial benefit of AR and the ability of Bcl-XL expression to
predict the response to AR in patients with MIBR-SCC
of the bladder.
Methods
The current study included 71 patients, (47 males and
24 females) with histologically proven MIBR-SCC of the
bladder (Stage pT2a-T3N0-N3M0) of different grades
(grade 1 to 3).
All patients underwent radical cystectomy for male
patients and anterior pelvic exenteration for female
patients in the period from January 2005 to December
2006 in the South Egypt Cancer Institute and the
department of urology, faculty of medicine, Assuit Uni-
versity. The presence of Schistosoma haematobium eggs
in the cystectomy specimens was an inclusion criterion.
Every patient was offered the information about the
effects, benefits and possible side effect of adjuvant
radiotherapy. The patients were free to choose to be
treated according to the international routine treatment
of bladder SCC which is radical cystectomy alone, or to
be subjected to the routine of our institute, which is
radical cystectomy followed by radiotherapy.
Among those, 38 patients (group 1) agreed to receive
AR to the pelvis 3 weeks after cystectomy. AR was given
in the dose of 50Gy/25 fractions/5 weeks using linear
accelerator (Siemens Mevatron) 6 - 15 MV Photons at
100 cm source axis distance. The upper border of the
target was the junction of L5 - S1 vertebrae, the lower
border was the lower margin of the obturator foramen.
The lateral borders were 1.5 cm lateral to the pelvic
brim, the anterior border was the anterior of the sym-
physis pubis and the posterior border included the ante-
rior one third of the rectum. Three fields’ technique
(one anterior and 2 lateral wedged fields) was used. This
arrangement is supposed to give a homogenous distribu-
tion to the target volume. The remaining 33 patients
(group 2) refused AR based on different social and cul-
tural backgrounds, such as how far they lived from the
institute (sometimes more than 500 KM) and some pre-
valent exaggerated concerns about the side effects of
radiotherapy, sometimes potentiated by personal pre-
vious experience of a relative of the patient.
Study scientific approval was obtained from the urol-
ogy department scientific board and ethically approved
by the ethics committee of the Faculty of Medicine,
Assiut University (that conforms to the provisions of the
Declaration of Helsinki). Informed written consents
were obtained from all patients before enrollment in the
study with guarantee of confidentiality.
Formalin fixed, paraffin embedded tissue from parts of
the cystectomy specimens from all 71 patients were
used for ordinary histopathological studies. Immunohis-
tochemical characterization for Bcl-XL expression was
done by the indirect immuno-peroxidase technique
using the kit produced by LAB VISION Corporation. It
is supplied as total IgG purified from rabbit anti-serum
by protein A chromatography. It is prepared at 1 mg/ml
in 10 mM PBS (Phosphate-buffered saline), ph 7.4.
Staining Protocol
Tissue sections (4 μm thick) were cut immediately before
staining and were heated to 56°C for 20 minutes. Protein
blocking was accomplished through application of Ultra V
block for 5 minutes and application of 5% normal Goat
serum for 30 minutes. The primary antibody was applied
in a concentration of 1:400 and was incubated in a moist
humidity chamber overnight. Biotinylated Goat Anti-poly-
valent was then applied and incubated for 10 minutes at
room temperature. Streptavidin Peroxidase was then
applied and incubated for 10 minutes at room tempera-
ture. One drop (40 μl) of Diaminobenzidine Chromogen
was added to 1 ml of Diaminobenzidine Substrate (mixed
by swirling) and the mixture was then applied to the tissue
sections and incubated for 5 minutes. The sections were
counterstained with Mayer’s hematoxylin for few seconds.
Tissue samples with known expression for the marker
(colon carcinoma stained with anti- Bcl-XL) served as
positive control. Negative controls were sections treated
as described above, but with the primary antibody
replaced with pooled non-immune mouse IgG of the
same concentration.
All sections were analyzed with a BX-40 bright field
microscope under X10-20 objectives. When questions
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tions were reviewed for confirmation. Staining was clas-
sified as negative when no or weak (less than 20%)
expression of the anti-apoptotic marker Bcl-XL was
observed within the cytoplasm of tumor cells. Staining
was classified as positive when significant uniform cyto-
plasmic expression of the anti-apoptotic marker Bcl-XL
(greater than 20%) was observed within the cytoplasm of
tumor cells.
Follow up of all patients for 3 years after cystectomy
or until recurrence had occurred was done every 3
months and included clinical examination, serum creati-
nine, alkaline phosphatase, abdominal ultrasonography
and chest x-ray. Abdominal computerized tomography
and bone scans were done when findings suggested dis-
ease progression, defined as any emerging local or dis-
tant tumor.
Statistical analysis
All data were analyzed using SPSS (Statistical Program
for Social Sciences version 16 for windows, 2001, SPSS
I n c . ,C h i c a g o ,I L ,U S A ) .U n i v a r i a t ea n a l y s i sw a sd o n e
using chi-square test with Fisher’s exact correction and
independent T test. Multivariate analysis was done using
Logistic regression analysis to identify the most impor-
tant risk factor for recurrence, the Kaplan Meier survival
analysis with log rank p value was done to compare the
effect of radiotherapy on recurrence. The effect of radio-
therapy was adjusted to age group (older or younger
than 50 years), sex, tumor size (≥ or <3 cm), stage (≥ or
< stage III), grade, lymph node involvement and Bcl-XL
expression as univariate predictors. Cox regression was
done to test the significant factors as multivariate pre-
dictors of the efficacy of AR. P value < 0.05 was consid-
ered to be significant.
Results
Table 1 shows the tumor characteristics in both treat-
ment groups, there was no significant difference
between both groups as regards clinico-pathological
characteristics.
Using recurrence as a dependent factor, comparing
the 2 groups (recurrence and no recurrence) concerning
different predictors associated with recurrence, table 2
showed no statistical difference between the 2 groups
except for Bcl-XL expression, tumor grade and AR.
Recurrence occurred in 89.7% and 23.8% among patients
with positive and negative Bcl-XL expression respec-
tively (p-value < 0.0001). Recurrence was more asso-
ciated with grade 2 and 3 tumors (59.4%, 78.6%
respectively) with a p-value 0.002. Recurrence was noted
in 39.5% of patients who were offered AR while in
63.6% of patients who were not offered AR (p-value
0.04).
Table 1 Patients’ clinicopathological data
Total AR AR not
done
N
(71)
%N
(38)
%N
(33)
%P
-value
Age (Ys) <50 37 52.1% 22 57.9% 15 45.5% 0.2
≥50 34 47.9% 16 42.1% 18 54.5%
Sex Male 47 66.2% 24 63.2% 23 69.7% 0.4
female 24 33.8% 14 36.8% 10 30.3%
Tumor
size
Small
(<3 cm)
23 32.4% 9 23.7% 14 42.4% 0.07
Large
(≥3 cm)
48 67.6% 29 76.3% 19 57.6%
Stage T 2a 11 15.5% 7 18.4% 4 12.1% 0.5
T 2b 50 70.4% 27 71.1% 23 69.7%
T 3 7 9.9% 2 5.3% 5 15.2%
T 4a 3 4.2% 2 5.3% 1 3.0%
Grade 1 25 35.2% 16 42.1% 9 27.3% 0.09
2 32 45.1% 18 47.4% 14 42.4%
3 14 19.7% 4 10.5% 10 30.3%
LN +ve 10 14.1% 3 7.9% 7 21.2% 0.3
-ve 39 54.9% 23 60.5% 16 48.5%
Missing
data
22 31.0% 12 31.6% 10 30.3%
Bcl-XL -ve 42 59.2% 23 60.5% 19 57.6% 0.5
+ve 29 40.8% 15 39.5% 14 42.4%
AR: Adjuvant radiotherapy; LN: Lymph nodes; +ve: positive; -ve: negative.
Table 2 Univariate analysis for Factors associated with
recurrence
Recurrence
Variable Yes
(n = 36)
No
(n = 35)
p-
value
Age (mean ± SD) 48.8 ±
10.03
45.8 ± 9.22 NS**
Sex Male 22(46.8%) 25 (53.2%) NS*
Female 14 (58.3%) 10 (41.7%)
Bcl-XL expression -ve 10 (23.8%) 32 (76.2%) 0.000*
+ve 26 (89.7%) 3(10.3%)
Histo-pathologic
Grade
Grade 1 6 (24%) 19 (76%) 0.002*
Grade 2 19(59.4%) 13(40.6%)
Grade 3 11(78.6%) 3(21.4%)
Radiotherapy Done 15 (39.5%) 23 (60.5%) 0.04*
Not Done 21 (63.6%) 12 (36.4%)
Stage Stage 1-2 31(50.8%) 30(49.2%) NS*
Stage 3 5 (50%) 5(50%)
Tumor Size Small < 3 cm 9(39.1%) 14(60.9%) NS*
Large > 3 cm 27 (56.2%) 21(43.8%)
** Independent T test, * Fisher Exact test.
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most predicting factors associated with recurrence, posi-
tive Bcl-XL expression was the most significant factor
(Odd’s ratio 41.1, 95% confidence interval (CI): 8.4 -
102.3 and p - value 0.000) followed by AR which was a
protective factor (Odd’s ratio 0.19, 95% CI: 0.05 - 0.78
and p - value 0.02) (table 3)
With Cox regression analysis, the only independent
multivariate predictor of radio-sensitivity was the Bcl-
XL expression with odd ratio 4.6, 95% CI 2.2 - 9.6 and a
p value < 0.0001.
After 3 years follow up the disease free cumulative
survival was 48% for those who received AR (mean dis-
ease free survival of 26 ± 2 months; 95% CI: 22 - 31
months, median survival 18 months) while it was only
29% for those who did not (mean disease free survival
of 18 ± 3 months; 95% CI: 13 - 23 months, median sur-
vival 12 months) (log rank p value 0.03) (Figure 1).
All the patients tolerated the treatment protocol with
no life threatening toxicity or complications and in no
patients the radiotherapy schedule had to be interrupted
due to side effects. According to the national cancer
institute classification of common toxicity [12], the side
effects were in the form of diarrhea grade 1(increase of
<4 stools/day) in 11(29%) and diarrhea grade 2 (increase
of 4-6 stools/day or nocturnal stools) in 10 (26%)
patients. All patients responded to simple anti-diarrheal
treatment within one month. No late complications
(including intestinal obstruction) were encountered in
our patients in the period of follow up.
Discussion
In this study 71 patients had radical cystectomy (or
anterior pelvic exenteration) for MIBR-SCC of the blad-
der. Thirty eight patient received AR, while 33 refused
it. A lot of cultural, and socioeconomic factors affected
the patients’ choice, and although we couldn’tj u s ta l l o -
cate the patient into treatment groups because we could
neither deny the patient a chance of a possible beneficial
treatment (based on our experience), nor we could force
the patient to comply with our routine which is still
controversial. Yet, this still appears as a limitation to the
study as it is not a formal way to randomize patients
between treatment groups.
The 3 years mean disease free survival was 26 months
for patients who received AR and 18 months for those
who did not. Fifty percent of the relapses in the “no
radiotherapy” group occurred within 3 months after the
operation, in our opinion this supports the concept of
gaining more local control via AR. The early recurrence
that would occur within 3 months of the operation
seems to be prevented by AR. Afterwards, the rates are
not very different from the AR group, however, the
recurrence rate is much less in the AR group because
there is much less recurrences within the first 3 months.
These results are further support to those obtained by
other investigators who valued the use of AR for MIBR-
SCC of the bladder.
In a controlled randomized study, Zaghloul et al. com-
pared cystectomy alone with cystectomy plus AR, using
two different fractionation schedules. The 5-year disease
free survivals were 49% and 44% in the two AR groups
respectively, compared to 25% in the radical cystectomy-
alone group [13].
In spite of the small sample size, the results of our
s t u d ys u p p o r tt h ec a s ef o rA Ri nM I B R - S C Co ft h e
bladder. The rationale behind this practice is multifac-
torial. Looking at the patterns of recurrence after
cystectomy, large surgical series suggest that local fail-
ures with or without distant metastasis occur in about
13% to 30% of all patients [14]. This percentage reaches
75% in case of MIBR-SCC [3]. Another factor is the
wide variation of the doctors’ practice towards lymph
node dissection during cystectomy. Although lymphade-
nectomy has a proven value in decreasing recurrence
after cystectomy, it seems that up to 60% of patients
going through cystectomy do not have lymphadenect-
omy [15]. Moreover, the effect of radiation on muscle
invasive bladder cancer in many bladder preservation
Table 3 Logistic regression analysis for Factors predicting
recurrence
Variables Wald p-value Odds Ratio 95% C.I
Lower Upper
Radiotherapy Done 5.317 0.02 0.19 0.05 0.78
Positive Bcl-XL
expression
20.907 0.000 41.1 8.4 102.3
R2 0.60
Figure 1 Kaplan Meier Survival analysis for the effect of
radiotherapy on cumulative disease free survival.
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is well appreciated [16].
These factors are in favor - in our opinion - of the use
of AR. Yet, this adjuvant therapy shouldn’t be promoted
as a replacement of lymphadenectomy.
The argument against AR is based on studies like Rei-
singer et al. who reported that bowel obstruction
occurred in 37% of patients who received AR compared
with 8% in those who did not [17].
The use of fractionated dose techniques and new tech-
nologies like the high-energy linear accelerator and
computed tomography planning that deliver the maxi-
mum dose to the area of interest with minimum radia-
tion hazard to the bowel decreases the rate of chronic
bowel complications to 12% [18].
In the current series acute bowel complications after
AR occurred in 21(55%) patients in the form of diarrhea
grade 1:2 according to the National Cancer Institute
classification [12]. No patient had intestinal obstruction
as a chronic complication of the treatment. The overall
advantage of AR as regards disease free survival in this
study was obvious.
Bcl-XL expression was the only significant predictor of
radio resistance. An explanation of this relationship
between Bcl-XL over-expression and radio-resistance is
that Bcl-XL resides in the outer mitochondrial mem-
brane inhibiting the apoptotic process through which
radiotherapy affects tumor cells [19]. Also, it was pre-
sumed that Bcl-XL confers radio-resistance by abrogat-
ing mitochondrial cytochrome-C release and activation
of caspase-3 [20]. This relation between Bcl-XL over-
expression and radio-resistance opens the way towards
better selection of the cases, hence getting the best
results as regards cancer control while avoiding the pos-
sible side effects of radiotherapy.
To our knowledge no comparable data could be found
in the available literature regarding the importance of
Bcl-XL expression as a predictor of the response to AR
among bilharzial or non- bilharzial bladder cancer
patients. However, the value of other anti apoptotic
markers’ expression (e.g. Bcl-2 and p53) in determining
radio-sensitivity of bladder cancer was tested. Bcl-2 and
p53 afforded similar protection against cell death on
irradiation as that afforded by Bcl-XL and a poor out-
come should be expected in patients treated with radio-
therapy for TCC of the bladder expressing both Bcl-2
and p53 [21]. Hence those patients should not be
offered the treatment on first place.
Conclusion
Adjuvant radiotherapy for muscle invasive bilharzial
related squamous cell carcinoma of the urinary bladder
i sap r a c t i c et h a ts h o u l db ec o n s i d e r e df o rr e e v a l u a t i o n
due to its potential effectiveness and minor side effects.
Moreover, Bcl-XL expression is a valuable tool for pre-
dicting the response to AR in those patients, hence
detecting patients who are most likely to benefit from
the adjuvant treatment.
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